NASDAQ:NYXH Nyxoah Q4 2025 Earnings Report $1.62 -0.14 (-7.95%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Nyxoah EPS ResultsActual EPS-$0.69Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANyxoah Revenue ResultsActual Revenue$6.62 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANyxoah Announcement DetailsQuarterQ4 2025Date2/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNyxoah's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Nyxoah Earnings HeadlinesNyxoah rises as trial win for Genio boosts case for label expansionSeptember 3 at 7:36 PM | msn.comNyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares JumpSeptember 3 at 9:34 AM | rttnews.comLabor Day Warning: The secret that called 1929 is flashing something newIn 1929, a young researcher named Irving Weiss spotted warning signs Wall Street ignored - then watched the Dow crash nearly 13% in a single day, followed by another 12% drop the next. His research became Weiss Ratings, a system The Wall Street Journal ranked number one for investment performance. It also called the Dot-Com Bust, the 2008 crisis, and the 2020 crash. Now the system is flagging a possible shift in the back half of 2026, separating stocks it flags as vulnerable from those positioned to climb.September 6 at 1:00 AM | Weiss Ratings (Ad)Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient StudySeptember 3 at 9:34 AM | finance.yahoo.comNyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsSeptember 2, 2026 | markets.businessinsider.comNyxoah Updates Share Count and Potential Dilution From Convertible InstrumentsAugust 25, 2026 | tipranks.comSee More Nyxoah Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email. Email Address About NyxoahNyxoah (NASDAQ:NYXH), headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality. The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy. Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.View Nyxoah ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t IgnoreOllie's Bargain Outlet Stock Falls on Weak Comps Despite Margin GainsWhy Hewlett Packard Enterprise’s Sell-Off May Not LastSnowflake’s AI Momentum Is Forcing a Fresh Look at the Stock Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
